Harbin Pharma Q2 Report: New Accounting Rules, Impairment Reserves, & Investor Briefing Revealed
Harbin Pharmaceutical Group discloses 2026 mid‑year results, new accounting policies and an impairment reserve, showcasing transparency and strategic growth in China’s pharma market.
2 minutes to read